Senate HELP Committee Confirms Dr. Robert Califf as FDA Commissioner

Statement of ACS CAN President Lisa Lacasse

January 13, 2022

Washington, D.C. – Today the Senate Health, Education, Labor and Pension (HELP) Committee voted to confirm Robert Califf as the next commissioner of the Food and Drug Administration (FDA). Approval of Dr. Califf by the HELP Committee will allow for full Senate consideration.

A statement from Lisa Lacasse, president of American Cancer Society Cancer Action Network (ACS CAN) follows:

“From reviewing and approving innovative therapies, to being given the mandate to regulate the entire tobacco industry, the work of the FDA plays a critical role in the fight against cancer. Given the complex and far-reaching work of the agency on cancer patients and families, a confirmed commissioner is vital to the agency’s work. Once confirmed, we look forward to working with Dr. Califf at FDA to:

  • Enhance and elevate the patient voice in drug development and regulatory review within the agency;
  • Modernize and harmonize diagnostic test oversight to provide patients and their providers with confidence in their test results;
  • Ensure that new drugs are developed and reviewed in a way that accounts for the broad diversity of patients with cancer;
  • Prohibit all flavors in all tobacco products to prevent youth from initiating a lifelong, dangerous addiction to tobacco; and
  • Complete final review of all remaining applications of novel tobacco products, including e-cigarettes which evidence has shown to have enticed and addicted a new generation of tobacco users.

“On behalf of families affected by cancer, ACS CAN urges the Senate to quickly confirm Dr. Califf, so FDA can press forward on these critical issues that have impact on a disease that is expected to kill more than 609,000 Americans this year alone.”


Media Contacts

Emily Burr
Director, Media Advocacy
Washington, D.C.
Alissa Crispino
VP, Advocacy Communications and Policy
Washington, D.C.